1. Pharmacokinetics and Pharmacodynamics of Arterolane Maleate Following Multiple Oral Doses in Adult Patients With P. falciparum Malaria.
- Author
-
Gautam, Anirudh, Ahmed, Tausif, Sharma, Pradeep, Varshney, Brijesh, Kothari, Monika, Saha, Nilanjan, Roy, Arjun, Moehrle, Joerg J., and Paliwal, Jyoti
- Subjects
- *
PHARMACODYNAMICS , *DATA analysis software , *BLIND experiment , *TREATMENT effectiveness , *DISEASE relapse , *DRUG development , *EXPERIMENTAL therapeutics , *RESEARCH funding , *RESEARCH , *POLYMERASE chain reaction , *PARASITOLOGY , *HEALTH outcome assessment , *MEDICAL cooperation , *MASS spectrometry , *LIQUID chromatography , *DOSE-effect relationship in pharmacology , *COMBINATION drug therapy , *ANTIMALARIALS , *ANALYSIS of variance , *DRUG therapy for malaria , *THERAPEUTICS - Abstract
Arterolane (RBx 11160) maleate is a novel, rapidly acting synthetic trioxolane antimalarial compound being developed by Ranbaxy Research Laboratories (Haryana, India). It is presently under phase III in combination with piperaquine phosphate. The present work reports the relationship between pharmacokinetic (PK) parameter (AUC0-8h on day 0/day 6) and indices of pharmacodynamic (PD) response (50% parasite clearance [PC50], 90% parasite clearance [PC90], parasite clearance time [PCT], recrudescence) from a phase II, double-blind, multicenter, randomized, parallel-group, dose-ranging trial. Patients with acute uncomplicated P. falciparum malaria were randomized to 1 of 3 arterolane maleate (50, 100, and 200 mg) doses for 7 consecutive days. Plasma concentration data were available from 78, 76, and 75 patients receiving a 50-, 100-, and 200-mg dose, respectively. Based on PD modeling, its limitations and assumptions, minimum 150-mg dose arterolane maleate was recommended to optimize the probability of maximum therapeutic benefits for an adult. Doses higher than 100 mg are unlikely to reduce the probability of recrudescence. This study re-stresses the need of combining short and long-acting drugs to prevent resistance development and minimize recrudescence. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF